公开(公告)号：US20070237759A1

公开(公告)日：2007-10-11

申请号：US11704529

申请日：2007-02-08

申请人： George Virca ,  Shaw-Fen Hu

发明人： George Virca ,  Shaw-Fen Hu

IPC分类号： A61K39/395 ,  C07K16/00 ,  C12N5/06 ,  C12P21/00

CPC分类号： C07K16/28 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.

摘要翻译： 本发明提供了与抗PAR-2抗体有关或衍生自抗PAR-2抗体的组合物和方法。 在具体实施方案中，本发明提供了结合人PAR-2，PAR-2-结合片段和此类抗体衍生物的抗体，以及包含此类片段的PAR-2结合多肽。 其他实施方案提供编码此类抗体，抗体片段和衍生物和多肽的核酸，包含此类多核苷酸的细胞，制备此类抗体的方法，抗体片段和衍生物和多肽，以及使用此类抗体，抗体片段和衍生物和多肽的方法，包括方法 治疗或诊断患有PAR-2相关疾病或病症的受试者。

公开(公告)号：US20070071764A1

公开(公告)日：2007-03-29

申请号：US11406454

申请日：2006-04-17

申请人： John Sullivan ,  Joseph McGivern ,  Leslie Miranda ,  Hung Nguyen ,  Kenneth Walker ,  Shaw-Fen Hu ,  Colin Gegg ,  Stefan McDonough

发明人： John Sullivan ,  Joseph McGivern ,  Leslie Miranda ,  Hung Nguyen ,  Kenneth Walker ,  Shaw-Fen Hu ,  Colin Gegg ,  Stefan McDonough

IPC分类号： A61K39/395 ,  C07K16/46

CPC分类号： A61K47/48215 ,  A61K38/00 ,  A61K47/60 ,  C07K14/43504 ,  C07K2319/30 ,  C07K2319/55

摘要： Disclosed is a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c  (I) and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.